G. Roodman

Discover medicine · 2004

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 13 researchers here, as inferred from the citation graph.

Whom G. Roodman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Mundy

Who trusts G. Roodman overall

  1. Y. Mao
  2. A. F. Stewart
  3. E. Eriksen
  4. E. Keller
  5. R. Langley
  6. O. De Wever
  7. D. Garfield
  8. R. Taichman
  9. P. Steeg
  10. K. Shen

Papers from G. Roodman's perspective

Ordered by how strongly the researchers G. Roodman trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension (Nature Genetics)
  2. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist (EMBO Journal)
  3. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. (American Journal of Human Genetics)
  4. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. (Journal of Clinical Oncology)
  5. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. (Journal of the National Cancer Institute)
  6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. (Cancer Journal)
  7. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. (Journal of Clinical Oncology)
  8. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (New England Journal of Medicine)
  9. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). (Human Molecular Genetics)
  10. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. (Blood)

Their papers